Seventh Sense Biosystems, Inc. (7SBio), a Medford, MA-based maker of a push-button blood collection device, raised $10M in Series C funding.
Backers included existing investors Novartis ($ADR), Laboratory Corporation of America® Holdings, Polaris Partners and Flagship Ventures. In conjunction with the funding, Marc Ceulemans, Novartis Head Strategic Venture Capital & Pharma Equities, and Don Hardison, former CEO of Good Start Genetics, have joined Seventh Sense’s Board of Directors.
The company will use the funds to develop new products and to expand production capacity.
Led by Howard Weisman, CEO, and newly added Chief Business Officer Stuart Blitz, Seventh Sense Biosystems has designed and developed TAP™, a first push-button blood collection device. The device – currently under FDA 510(k) review and not yet for sale – is positioned on a patient’s upper arm and blood is
Future versions of TAP will be designed to enable the patient to collect their own blood anywhere and anytime.